Get started
Author

Timothea Konstantinou

Observed name: Konstantinou, Timothea
ORCID: 0009-0000-8676-1350
Observed ORCID: 0009-0000-8676-1350
OpenAlex ID: A5046370252
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy
2025 · Eeson Rajendra, Claudio A Lademann, et al. · Nucleic Acids Research · 7
The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
2026 · Helen M.R. Robinson, Vera Grinkevich, et al. · Clinical Cancer Research · 2
Development of a Xenopus-based assay for high-throughput evaluation of mucociliary flow
2023 · Ioanna Antoniades, Andria Koulle, et al. · European Respiratory Journal · 1
Development of a Xenopus -based assay for high-throughput evaluation of mucociliary flow
2022 · Ioanna Antoniades, Andria Koulle, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Data from The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
2026 · Helen M.R. Robinson, Vera Grinkevich, et al.
Supplementary Data1 from The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
2026 · Helen M.R. Robinson, Vera Grinkevich, et al.
Abstract 246: Discovery and mechanistic characterisation of the first oral bioavailable FEN1 inhibitor for treatment of HRD and EWS cancers and combination with various DDR inhibitors.
2026 · Lars T. Burgdorf, Julien Lefranc, et al. · Cancer Research
Evaluating the role of Metformin on DNA damage and DNA damage response in ovarian cancer
2014 · Timothea Konstantinou · University of Birmingham Institutional Research Archive (University of Birmingham)
PDF
Works count: 9
Citation count: 11
H-index: 2
I10-index:
Year
Topic
Type